Published in Clinical Trials Week, May 11th, 2009
Data will be presented on the safety, tolerability and effectiveness of ACU-4429, a single-dose daily oral treatment for dry AMD, the most common form of the disease. All forms (wet and dry) of age-related macular degeneration affect more than 1.75 million people in the United States and are expected to increase to almost 3 million by 20201. Currently, there is no approved medicinal therapeutic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.